Bruker (NASDAQ:BRKR) Price Target Raised to $55.00 at JPMorgan Chase & Co.

Bruker (NASDAQ:BRKR) had its price objective upped by JPMorgan Chase & Co. from $50.00 to $55.00 in a research note issued to investors on Monday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

Other research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bruker in a research note on Monday, December 1st. Zacks Research raised shares of Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. Bank of America lifted their price objective on shares of Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a report on Monday. Rothschild Redb upgraded shares of Bruker to a “strong-buy” rating in a report on Thursday, November 20th. Finally, TD Cowen lifted their price target on Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $52.86.

Bruker Price Performance

Bruker stock opened at $45.67 on Monday. The stock’s 50 day moving average price is $41.86 and its two-hundred day moving average price is $38.39. The stock has a market capitalization of $6.94 billion, a price-to-earnings ratio of -285.44, a PEG ratio of 6.64 and a beta of 1.17. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85. Bruker has a 52-week low of $28.53 and a 52-week high of $64.64.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. During the same period in the prior year, the firm earned $0.60 earnings per share. Bruker’s revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities analysts predict that Bruker will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, December 8th. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

Insiders Place Their Bets

In other Bruker news, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares in the company, valued at $1,373,268. This represents a 15.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its holdings in Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after buying an additional 487 shares during the last quarter. Allworth Financial LP boosted its stake in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the last quarter. Huntington National Bank grew its position in shares of Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 645 shares during the period. Spire Wealth Management purchased a new stake in shares of Bruker during the 2nd quarter worth approximately $32,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after purchasing an additional 745 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.